ArticleCureus2025
Giant Cell Arteritis in the Third Decade of Life: A Case for Expanded Clinical Suspicion.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA), also known as temporal arteritis, is the most common idiopathic systemic vasculitis in middle-aged adults, predominantly involving large and medium-sized arteries. We report an unusual case of a 34-year-old woman with a five-year history of migraines who developed symptoms, including headache, transient vision loss, jaw claudication, and a 5 kg weight loss over two months. Physical examination revealed scalp tenderness, with no other notable findings. Laboratory investigations showed an elevated erythrocyte sedimentation rate (ESR) of 85 mm/hr and a C-reactive protein (CRP) level of 50 mg/L. Ultrasound of the temporal artery demonstrated thickening with the characteristic "halo" sign, and a biopsy confirmed inflammatory changes with multinucleated giant cells. Treatment with high-dose prednisolone resulted in remission, and the patient was discharged with a follow-up plan in place. GCA predominantly affects the superficial temporal arteries, with irreversible vision loss being its most serious complication. Prompt diagnosis and treatment are critical. The diagnosis relies on clinical features, elevated inflammatory markers, imaging studies, and histopathological confirmation. According to the European Alliance of Associations for Rheumatology (EULAR) guidelines, temporal artery ultrasound showing a non-compressible "halo" sign is recommended for diagnosis. Further studies are needed to investigate the potential connection between migraines and GCA. This case underscores the rarity of GCA in individuals under 50 and highlights the possibility of GCA developing in younger patients with a longstanding history of migraines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.